Combination Biologic Therapy without Chemotherapy as Initial Treatment for Mantle Cell Lymphoma: Multi-Center Phase II Study of Lenalidomide plus Rituximab
The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the UK is poised to undergo a dramatic shift during the forecast period. Disease management of the four largest B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL), currently revolves around multiple rounds of Rituxan-based chemotherapy. See full Report : http://bit.ly/1vMz8VJ
UO-Ematologia CTMO Fondazione Policlinico, Mangiagalli Regina Elena, ... the goal of chemoterapy was purely palliative in intent. alkylators were the only therapy ...
Blum K A, Lozanski G, Byrd J C. Adult Burkitt Leukemia and lymphoma. Blood 2004;104:3009-3020 ... Blum K A, Lozanski G, Byrd J C. Adult Burkitt Leukemia and ...
Key conclusions The addition of rituximab to fludarabine during induction therapy for CLL patients improved CR rates and response duration without an increase in ...